Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheap arthritis drug could tame severe eczema

NCT ID NCT00809172

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether methotrexate, an older drug used for arthritis, works as well as cyclosporine for people with moderate to severe atopic dermatitis (eczema). One hundred adults received either drug for 24 weeks. The main goal was to see if eczema severity dropped by half after 8 weeks. Researchers also tracked quality of life and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methotrexate and cyclosporine
What this could lead to
If methotrexate works as well as cyclosporine, it could offer a safer long-term option for controlling severe eczema.
What could go wrong
This is a small, completed trial comparing two existing drugs. Neither is a cure, and both have side effects like kidney or liver risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

100 people

The number who actually took part.

Start date

Dec 2008

Finished

Apr 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged \> 18 years old. * Both genders eligible for study. * Moderate to severe AD. * Scorad \> 15. * Participants must use a contraceptive method during the trial and for 3 months after the end of the trial for female and 5 months for male participants. * Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol. * Patients must be registered in a social security system or with a health insurance coverage. Exclusion Criteria: * Pregnant or lactating women. * Evolutive skin disease. * Patients with a clinically significant disease (chronic, recurrent or active). * Systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid the week before the inclusion. * Contra-indication to methotrexate and cyclosporine. * Exposure to phototherapy: cumulative dose \> 2000 J/cm2. * Patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision. * Patients under a protection measure. * Patients in a critical medical situation. * Patients with a personal situation evaluated by the investigator as unable to give optimal participation to the study, or where the study could constitute a risk for the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Hospices Civils de Lyon

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.